Trial · NCT07885215
Effects of Respiratory Muscle Strengthening and Diaphragmatic Breathing on Shoulder Pain and Disability
NCT07885215, Not applicable, Recruiting, Zonguldak Bulent Ecevit University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Respiratory Muscle Strengthening and Diaphragmatic Breathing on Shoulder Pain and Disability. Trials, record NCT07885215. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885215
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Respiratory Muscle Strengthening and Diaphragmatic Breathing on Shoulder Pain and Disability
- NCT number
- NCT07885215
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Zonguldak Bulent Ecevit University
- Conditions
- Shoulder Pain, Sleep Quality, Lung Cavity, Pain Intensity
- Interventions
- shoulder rehabilitation, respiratory muscle strengthening exercises and diaphragmatic breathing exercises
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Shoulder Pain and Disability Index (SPADI) Score | Baseline and 3 weeks after baseline | Shoulder pain and disability will be assessed using the Shoulder Pain and Disability Index (SPADI). The SPADI consists of 13 items divided into two subscales: pain (5 items) and disability (8 items). The total score ranges from 0 to 100, with higher scores indicating greater pain and disability. Assessments will be performed at baseline and at the end of the three-week intervention. |
| Secondary | Change in Shoulder Pain Intensity (VAS) | Baseline and 3 weeks after baseline | Pain intensity at rest, during activity, and at night, measured using a 0-10 cm Visual Analog Scale. Higher values indicate greater pain. |
| Secondary | Change in Pulmonary Function (FVC) | Baseline and 3 weeks after baseline | Forced vital capacity measured by spirometry, expressed in liters. |
| Secondary | Change in Pulmonary Function (FEV1) | Baseline and 3 weeks after baseline | Forced expiratory volume in one second, measured by spirometry, expressed in liters. |
| Secondary | Change in FEV1/FVC Ratio | Baseline and 3 weeks after baseline | Ratio of forced expiratory volume in one second to forced vital capacity, expressed as a percentage. |
| Secondary | Change in Peak Expiratory Flow (PEF) | Baseline and 3 weeks after baseline | Peak expiratory flow measured using spirometry. |
| Secondary | Change in Shoulder Range of Motion | Baseline and 3 weeks after baseline | Active and passive shoulder range of motion measured using a universal goniometer, expressed in degrees. |
| Secondary | Change in Modified Constant-Murley Score | Baseline and 3 weeks after baseline | Shoulder pain, daily activities, range of motion, and strength assessed on a 0-100 scale. Higher scores indicate better shoulder function. |
| Secondary | Change in Western Ontario Shoulder Instability Index (WOSI) Score | Baseline and 3 weeks after baseline | The Western Ontario Shoulder Instability Index (WOSI) will be used to assess shoulder-related physical symptoms, sports/recreation/work, lifestyle, and emotional functioning. The questionnaire consists of 21 items, with a total score ranging from 0 to 2100. Higher scores indicate greater shoulder-related impairment and poorer quality of life. |
| Secondary | Change in Pittsburgh Sleep Quality Index (PSQI) | Baseline and 3 weeks after baseline | Sleep quality assessed using the PSQI global score, ranging from 0 to 21. Higher scores indicate poorer sleep quality. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885215
GET https://conductscience.org/api/trials/v1/NCT07885215/registered